The Relation between the Uric Acid Levels and the Recanalization Times in Patients with Cerebral Venous Thrombosis

Year 2022, Volume: 5 Issue: 3, 417 - 423, 01.09.2022

Fatma Şimşek

https://doi.org/10.19127/bshealthscience.1081778

Abstract

Recanalization times in cerebral venous thrombosis (CVT) patients are generally around six months, but do vary from patient to patient. The reasons for the variation in the recanalization times between the CVT patients are still a matter of debate. Thus, in this study, the relation between the uric acid (UA) level, which has been shown to have antioxidant properties in ischemic stroke, and the recanalization time in CVT patients was investigated. In this context, the CVT patients, who were followed up between January 2015 and May 2020, were analyzed retrospectively. Of the 78 patients, who met the eligibility criteria to be included in the research, 76.9 % were female and 23.1 % were male. It was determined that headache was the most common (73.1 %) symptom, and that the gynecological reasons were the most common (38.5 %) etiological reasons. A weakly significant negative correlation was found between the UA levels and the recanalization times in the study group (P = 0.003, r= -0.327). There was a weakly negative correlation between the UA levels and the recanalization times in female patients (P = 0.046, r= -0.259). The UA levels of male patients were also found to be negatively correlated with the recanalization times, albeit not statistically significantly. The finding that the recanalization times were shortened as UA levels were increased in female CVT patients was interpreted as that there is a gender-specific relationship between the UA levels and the recanalization times in CVT patients.

Keywords

Cerebral venous thrombosis, Uric acid, Recanalization, Gender, Prognosis

References

• Arauz A, Vargas-González JC, Arguelles-Morales N, Barboza MA, Calleja J, Martínez-Jurado E, Merino JG. 2016. Time to recanalisation in patients with cerebral venous thrombosis under anticoagulation therapy. J Neurol, Neurosurg, Psychiat, 87(3): 247-251.
• Baumgartner RW, Studer A, Arnold M, Georgiadis D. 2003. Recanalisation of cerebral venous thrombosis. J Neurol Neurosurg Psychiat, 74(4): 459-461.
• Becker BF. 1993. Towards the physiological function of uric acid. Free Radic Biol Med, 14(6): 615-631.
• Coutinho JM, Ferro JM, Canhao P, Barinagarrementeria F, Cantu C, Bousser MG, Stam J. 2009. Cerebral venous and sinus thrombosis in women. Stroke, 40(7): 2356-2361.
• Ferro JM, Canhao P, Bousser MG, Stam J, Barinagarrementeria F, Investigators I. 2005. Cerebral vein and dural sinus thrombosis in elderly patients. Stroke, 36(9): 1927-1932.
• Ferro JM, Canhão P, Stam J, Bousser MG, Barinagarrementeria F. 2004. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke, 35(3): 664-670.
• Ferro JM, Canhao P, Stam J, Bousser MG, Barinagarrementeria F, Investigators, I. 2004. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke, 35(3): 664-670. doi:10.1161/01.STR.0000117571.76197.26
• Gazioglu S, Eyuboglu I, Yildirim A, Aydin CO, Alioglu Z. 2017. Cerebral venous sinus Thrombosis: Clinical Features, Long-Term outcome and recanalization. J Clin Neurosci, 45, 248-251. doi:10.1016/j.jocn.2017.07.028
• Herweh C, Griebe M, Geisbusch C, Szabo K, Neumaier-Probst E, Hennerici MG, Nagel S. 2016. Frequency and temporal profile of recanalization after cerebral vein and sinus thrombosis. Eur J Neurol, 23(4): 681-687. doi:10.1111/ene.12901
• Herweh C, Griebe M, Geisbüsch C, Szabo K, Neumaier‐Probst E, Hennerici M, Nagel, S. 2016. Frequency and temporal profile of recanalization after cerebral vein and sinus thrombosis. European J Neurol, 23(4): 681-687.
• Hiltunen S, Putaala J, Haapaniemi E, Tatlisumak T. 2016. Long-term outcome after cerebral venous thrombosis: analysis of functional and vocational outcome, residual symptoms, and adverse events in 161 patients. J Neurol, 263(3): 477-484.
• Iranmanesh F, Sheykholeslami NZ, Gadari F, Ahmady J. 2012. Acute ischemic non-embolic stroke and serum level of uric acid. Iran J Neurol, 11(1): 1-5.
• Justicia C, Salas-Perdomo A, Perez-de-Puig I, Deddens LH, van Tilborg GAF, Castellvi C, Planas AM. 2017. Uric acid is protective after cerebral ischemia/reperfusion in hyperglycemic mice. Transl Stroke Res, 8(3): 294-305. doi:10.1007/s12975-016-0515-1
• Kanellis J, Kang DH. 2005. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin Nephrol, 25(1): 39-42. doi: 10.1016/j.semnephrol.2004.09.007.
• Lamani, S, Vishwanath, H. 2013. The role of serum uric acid in acute ischemic stroke. RJPBCS, 4(4): 350-357.
• Onetti Y, Dantas AP, Perez B, Cugota R, Chamorro A, Planas AM, Jimenez-Altayo F. 2015. Middle cerebral artery remodeling following transient brain ischemia is linked to early postischemic hyperemia: a target of uric acid treatment. Am J Physiol Heart Circ Physiol, 308(8): 862-874. doi:10.1152/ajpheart.00001.2015
• Putaala J, Hiltunen S, Salonen O, Kaste M, Tatlisumak T. 2010. Recanalization and its correlation to outcome after cerebral venous thrombosis. J Neurol Sci, 292(1-2): 11-15. doi:10.1016/j.jns.2010.02.017
• Saadat P, Ahmadi Ahangar A, Babaei M, Kalantar M, Bayani MA, Barzegar H, Frajzadeh F. 2018. Relationship of serum uric acid level with demographic features, risk factors, severity, prognosis, serum levels of vitamin d, calcium, and magnesium in stroke. Stroke Res Treat, 2018, 6580178. doi:10.1155/2018/6580178
• Saposnik G, Barinagarrementeria F, Brown RD, Jr Bushnell CD, Cucchiara B, Cushman M, deVeber G, Ferro JM, Tsai FY. 2011. Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke, 42(4): 1158-1192. doi:10.1161/STR.0b013e31820a8364
• Serdarevic N, Stanciu AE, Begic L, Uncanin S. 2020. Serum uric acid concentration in patients with cerebrovascular disease (ischemic stroke and vascular dementia). Med Arch, 742: 95-99. doi:10.5455/medarh.2020.74.95-99
• Sidhom Y, Mansour M, Messelmani M, Derbali H, Fekih-Mrissa N, Zaouali J, Mrissa R. 2014. Cerebral venous thrombosis: clinical features, risk factors, and long-term outcome in a Tunisian cohort. J Stroke Cerebrovasc Dis, 23(6): 1291-1295. doi:10.1016/j.jstrokecerebrovasdis.2013.10.025
• Singh VK, Jain N, Kalita J, Misra UK, Kumar S. 2020. Significance of recanalization of sinuses and resolution of parenchymal lesion in cerebral venous sinus thrombosis. J Clin Neurosci, 77, 175-180. doi:10.1016/j.jocn.2020.04.112
• Song B, Liu K, Gao Y, Zhao L, Fang H, Wang Y, Xu Y. 2018. Gender-specific relationship between uric acid levels and prognosis after cerebral venous thrombosis. Curr Neurovasc Res, 15(4): 292-297. doi:10.2174/1567202616666181127163321
• Stam J. 2005. Thrombosis of the cerebral veins and sinuses. N Engl J Med, 352(17): 1791-1798. doi:10.1056/NEJMra042354
• Stolz E, Trittmacher S, Rahimi A, Gerriets T, Rottger C, Siekmann R, Kaps M. 2004. Influence of recanalization on outcome in dural sinus thrombosis: a prospective study. Stroke, 352: 544-547. doi:10.1161/01.STR.0000112972.09096.65
• Talebi A, Amirabadizadeh A, Nakhaee S, Ahmadi Z, Mousavi-Mirzaei SM. 2020. Cerebrovascular disease: how serum phosphorus, vitamin D, and uric acid levels contribute to the ischemic stroke. BMC Neurol, 20(1): 116. doi:10.1186/s12883-020-01686-4
• Tiwari HS, Misra UK, Kalita J, Mishra A, Shukla S. 2016. Oxidative stress and glutamate excitotoxicity contribute to apoptosis in cerebral venous sinus thrombosis. Neurochem Int, 100, 91-96. doi:10.1016/j.neuint.2016.09.003
• Varga I, Ionescu I, Pascu I. 2011. Assessment of oxidative stress in patients with acute ischemic stroke. Bulletin of the Transilvania University of Brasov. Med Sci, 6(42): 43.
• Ya BL, Liu Q, Li HF, Cheng HJ, Yu T, Chen L, Bai B. 2018. Uric acid protects against focal cerebral ischemia/reperfusion-induced oxidative stress via activating Nrf2 and regulating neurotrophic factor expression. Oxid Med Cell Longev, 2018, 6069150. doi:10.1155/2018/6069150.